Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 6/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23334479 | 0.87 | HDAC1 (0.45) | HDAC1POLBMEN1KMT2AMAPT | |
| SCHEMBL23297255 | 0.86 | HDAC1 (0.42) | HDAC1POLBMEN1KMT2AMAPT | |
| SCHEMBL23334065 | 0.85 | HDAC1 (0.41) | HDAC1POLBMEN1KMT2AMAPT | |
| SCHEMBL26999049 | 0.85 | MET (0.51) | MEN1KMT2AMET | |
| SCHEMBL23528324 | 0.84 | MET (0.41) | MEN1KMT2ATP53MET | |
| SCHEMBL26626950 | 0.82 | MEN1 (0.42) | HDAC1POLBMEN1KMT2AMAPT | |
| SCHEMBL23334064 | 0.80 | HDAC1 (0.43) | HDAC1POLBMEN1KMT2AMAPT | |
| SCHEMBL26626269 | 0.80 | HDAC1 (0.43) | HDAC1POLBMEN1KMT2AMAPT | |
| SCHEMBL23297348 | 0.79 | HDAC1 (0.46) | HDAC1POLBMEN1KMT2AMAPT | |
| SCHEMBL29776807 | 0.79 | HDAC1 (0.46) | HDAC1POLBMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12240833-B2 | Pyridazinone compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| EP-3877367-B1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS INC (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20230338375-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230338375-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230048816-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2023-02-16 | — | — | US | disclosed |
| US-20230048816-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2023-02-16 | — | — | US | disclosed |
| US-11390606-B2 | Pyridazinone compounds and uses thereof | EDGEWISE THERAPECUTICS, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| WO-2021231630-A1 | SUBSTITUTED PYRIDAZINONE FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
| US-20210130327-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338375-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | IL6, MUSK, SMN1; SMN2 | HDAC1 444/4885POLB 1354/4885MEN1 4467/4885 |
| US-12240833-B2 | Pyridazinone compounds and uses thereof | IL6, IL1B, IL1A | HDAC1 333/4885POLB 1519/4885MEN1 4368/4885 |
| US-11390606-B2 | Pyridazinone compounds and uses thereof | IL6, IL1B, IL1A | HDAC1 333/4885POLB 1519/4885MEN1 4368/4885 |
| US-20210130327-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | IL6, IL1B, IL1A | HDAC1 333/4885POLB 1519/4885MEN1 4368/4885 |
| US-20230048816-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | IL6, IL1B, IL1A | HDAC1 333/4885POLB 1519/4885MEN1 4368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.